Hopper N et al.Increased sclerostin associated with stress fracture of the third metacarpal bone in the Thoroughbred racehorse.Bone Joint Res 7:94-102 (2018).
Wu J et al.Wnt-ß-catenin signaling pathway inhibition by sclerostin may protect against degradation in healthy but not osteoarthritic cartilage.Mol Med Rep 15:2423-2432 (2017).
Zhu M et al.Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer.Sci Rep 7:11399 (2017).
Wu L et al.Sclerostin expression in the subchondral bone of patients with knee osteoarthritis.Int J Mol Med 38:1395-1402 (2016).
Xu Y et al.Sclerostin is essential for alveolar bone loss in occlusal hypofunction.Exp Ther Med 11:1812-1818 (2016).
Thompson WR et al.Osteocyte specific responses to soluble and mechanical stimuli in a stem cell derived culture model.Sci Rep 5:11049 (2015).
Larson SR et al.Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.Prostate 73:932-40 (2013).
Cohen-Kfir E et al.Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor.Endocrinology 152:4514-24 (2011).
Mendoza-Villanueva D et al.Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFß-dependent expression of the Wnt antagonist, sclerostin.Breast Cancer Res 13:R106 (2011).
Mardaryev AN et al.Micro-RNA-31 controls hair cycle-associated changes in gene expression programs of the skin and hair follicle.FASEB J 24:3869-81 (2010).